207 completed, 74 unknown, 41 terminated, 24 recruiting. 383 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 383 | Completed 207, Unknown 74, Terminated 41, Recruiting 24, Not yet recruiting 17, Withdrawn 14, Active not recruiting 4, Enrolling by invitation 1, Suspended 1 |
Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daily Iron vs Every-other-day Iron for Pediatric Patients With IDA iron sulfate - Iron Deficiency Anemia | Phase 4 | Not yet recruiting | Loma Linda University | 100 | 2026-12-01 | 2026-07-10 |
| Sucrosomial Vs Intravenous Iron for Preoperative Anemia Treatment with oral sucrosomial iron, Treatment with intravenous iron - Anemia, Iron Deficiency Anemia | Phase 4 | Withdrawn | University of Rochester | 2026-12-01 | 2026-10-06 | |
| Plasmatic Biomarkers Associated With Short-term Luspatercept Treatment of Lower Risk Myelodysplastic Syndromes (MDS) Patients Luspatercept - Myelodysplasia | Phase 4 | Not yet recruiting | University Hospital, Grenoble | 150 | 2026-11-01 | 2026-09-21 |
| IRONCARE: Iron Treatment in Older Patients With Hip Fractures Ferric Derisomaltose, Oral Iron (Ferrous sulphate), Placebo IV - Hip Fracture, Anemia | Phase 4 | Not yet recruiting | University of Aarhus | 528 | 2026-10-01 | 2026-06-24 |
| Adaptive Platform Trial for Pain Management in Sickle Cell Vaso-Occlusive Crisis Group 02 Paracetamol + Morphine + Ketamine, Group 01 Control: Paracetamol + Morphine, Group 03 : Paracetamol + Morphine + Nefopam - Sickle Cell Disease, Vaso-occlusive Crisis | Phase 4 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 400 | 2026-10-01 | 2026-09-18 |
| Prophylactic Transfusion In Pregnant in Women With Sickle Cell Disease Prophylactic Transfusion Intervention group: Transfusion, Control group - Sickle Cell Disease, Pregnancy Related | Phase 4 | Withdrawn | Emory University | 2026-09-01 | 2026-10-19 | |
| Ferric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer Ferric Carboxymaltose (FCM), Iron Sucrose. - Gastric Cancer (GC), Iron Deficiency Anemia (IDA) | Phase 4 | Not yet recruiting | Zhaojian Niu,MD | 160 | 2026-08-01 | 2026-08-19 |
| Low Dose Bolus Ketamine For Use In Sickle Cell Pain Crisis Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses., Standard Care (in control arm) - Vaso-Occlusive Pain Episode in Sickle Cell Disease, Sickle Cell Disease (SCD) | Phase 4 | Not yet recruiting | University of Mississippi Medical Center | 400 | 2026-08-01 | 2026-07-06 |
| Integrating Point of Care Testing (POCT) For Newborn Screening and Early Care for Sickle Cell Disease in Yopougon, Côte d'Ivoire Gazelle-Multispectral point of care testing for newborn sickle cell disease screening; and initiation of early comprehensive clinical interventions - Sickle Cell Disease (SCD) | Phase 4 | Recruiting | Swiss Tropical & Public Health Institute | 120 | 2026-07-27 | 2026-10-05 |
| Anemia Therapy in Patients With Infective Endocarditis Adjunctive anemia therapy - Infective Endocarditis (IE), Severe Anemia | Phase 4 | Recruiting | Copenhagen University Hospital, Rigshospitalet | 74 | 2026-05-15 | 2026-05-29 |
| Maternal Fatigue After Postpartum Anemia Treatment With Intravenous Ferric Carboxymaltose and Oral Iron Therapy INTRAVENOUS FERRIC CARBOXYMALTOSE, oral iron therapy - Postpartum Fatigue, Iron Deficiency Anemia | Phase 4 | Completed | Pakistan Air Force (PAF) Hospital Islamabad | 134 | 2026-04-20 | 2026-10-19 |
| Tranexamic Acid for Bleeding Reduction During TURP Surgery Tranexamic Acid, Placebo (Normal Saline) - Benign Prostatic Hyperplasia, Transurethral Resection of the Prostate | Phase 4 | Recruiting | Hamza Najout | 80 | 2026-03-30 | 2026-10-09 |
| Alternate-day Versus Daily Oral Iron Therapy in Children With Iron Deficiency Anaemia Alternate-day oral Iron (III)-hydroxide polymaltose complex, Iron (III)-hydroxide polymaltose complex - daily oral dosing Iron (III)-hydroxide polymaltose complex - alternate-day oral dosing - Iron Deficiency Anemia | Phase 4 | Not yet recruiting | University of Medicine, Mandalay | 60 | 2026-02-01 | 2026-02-05 |
| The Role of Ferric Carboxymaltose in the Treatment of Pediatric Iron Deficiency Anemia in the Emergency Department Ferric Carboxymaltose (FCM), Ferrous Sulfate - Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease, Iron Deficiency Anaemia Due to Dietary Causes | Phase 4 | Not yet recruiting | Children's Hospital of Orange County | 150 | 2026-01-31 | 2026-02-17 |
| Acupoint TENS vs Resistance Training for Iron Deficiency Anemia Acupuncture transcutaneous electrical nerve stimulation (Acu-TENS), Resistance exercise training, Ferrous Sulfate - Iron Deficiency Anemia | Phase 4 | Recruiting | Cairo University | 60 | 2026-01-15 | 2026-05-26 |
| The Effect of Preoperative Intravenous Ferric Derisomaltose and EPO and Tranexamic Acid in Patients With Preoperative Anemia or Iron Deficiency in Bone Tumor isomaltose iron - Anemia | Phase 4 | Not yet recruiting | Tang Xiaodong | 160 | 2026-01-01 | 2026-01-02 |
| Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS Ravulizumab - aHUS, Atypical Hemolytic Uremic Syndrome | Phase 4 | Recruiting | Alexion Pharmaceuticals, Inc. | 20 | 2025-12-19 | 2026-04-20 |
| Efficacy and Tolerability of Sucrosomial® Iron vs Ferric Maltol in Iron Deficient Women Sucrosomial® Iron (Sideral® Forte), Ferric Maltol (Feraccru®) - Anemia, Iron Deficiency Anemia (IDA) | Phase 4 | Recruiting | Pharmanutra S.p.a. | 146 | 2025-12-11 | 2026-09-03 |
| Postoperative Intravenous Ferric Derisomaltose for Prevention of Long-term Anemia After Cardiac Surgery Ferric derisomaltose, Placebo (0.9% saline) - Anemia, Iron Deficiencies | Phase 4 | Not yet recruiting | Yonsei University | 180 | 2025-12-01 | 2025-11-20 |
| Levocarnitine for Reducing ESA Requirements in Hemodialysis Patients With Renal Anemia Levocarnitine Injection, Usual ESA-Based Anemia Care - Anemia, Kidney Failure | Phase 4 | Not yet recruiting | Shaikh Zayed Hospital, Lahore | 94 | 2025-09-15 | 2025-09-12 |
Showing 20 of 383. Sign in to see all of them.
Anemia, Iron-Deficiency (101) · Anemia, Sickle Cell (38) · Renal Insufficiency, Chronic (33) · Iron Deficiencies (30) · Kidney Failure, Chronic (21) · Anemia, Aplastic (19) · Thalassemia (17) · beta-Thalassemia (17) · Heart Failure (12) · Iron Overload (12) · Malaria (10) · Neoplasms (10) · Vaso-Occlusive Crises (10) · Kidney Diseases (9)
Hemic and Lymphatic Diseases (383) · Hematologic Diseases (379) · Nutritional and Metabolic Diseases (137) · Metabolic Diseases (134) · Iron Metabolism Disorders (125) · Anemia, Hypochromic (101) · Pathological Conditions, Signs and Symptoms (93) · Anemia, Hemolytic (83) · Iron Deficiencies (83) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (81) · Genetic Diseases, Inborn (79) · Urogenital Diseases (78) · Anemia, Hemolytic, Congenital (77) · Pathologic Processes (75)
ferric carboxymaltose (45) · ferrous sulfate (27) · Epoetin Alfa (22) · epoetin beta (19) · Iron (17) · Ferric Oxide, Saccharated (16) · Iron-Dextran Complex (16) · Darbepoetin alfa (15) · Sodium Chloride (15) · continuous erythropoietin receptor activator (13) · Cyclosporine (9) · Deferasirox (9) · ferric gluconate (9) · ferrous fumarate (9) · Saline Solution (8)
Hoffmann-La Roche (22) · Novartis Pharmaceuticals (13) · Amgen (11) · Peking Union Medical College Hospital (11) · Ain Shams University (7) · Watson Pharmaceuticals (7) · Ortho Biotech Products, L.P. (5) · University of Zurich (5) · Alexion Pharmaceuticals, Inc. (3) · American Regent, Inc. (3) · ApoPharma (3) · Assiut University (3) · Cairo University (3) · Duke University (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3)
United States (79) · China (38) · Egypt (24) · Spain (14) · United Kingdom (14) · Germany (13) · Italy (12) · France (11) · Switzerland (11) · Canada (10) · India (10) · Australia (8) · Israel (8) · Belgium (7) · Netherlands (7)
Bing Bing, PhD (3) · Bing Han, PhD (3) · Adel R. Rizkala, Pharm.D., MS (2) · Austin G Acheson, MD FRCS (2) · Fatma SE Ebeid, MD (2) · Gary Hoel, RPh, PhD (2) · Harry Tagbor, DrPH (2) · Janet Kwiatkowski, MD (2)
PMID 36791280, PMID 18328118, PMID 34932836, PMID 41114449, PMID 18828899, PMID 19208097, PMID 24363761, PMID 26504182, PMID 27881371, PMID 34710946, PMID 10100293, PMID 1090310, PMID 11796024, PMID 14616423, PMID 15824508, PMID 15953714, PMID 16177289, PMID 16273116, PMID 16520948, PMID 16614237, PMID 16737942, PMID 16977654, PMID 17035697, PMID 17108343, PMID 17267740, PMID 17296819, PMID 17396118, PMID 17400086, PMID 17522247, PMID 17620512, PMID 17622274, PMID 17694552, PMID 17962803, PMID 18008242, PMID 18067679, PMID 18216316, PMID 18284320, PMID 18298856, PMID 18343652, PMID 18565240, PMID 18632499, PMID 19034302, PMID 19075138, PMID 19149890, PMID 19212255, PMID 19236376, PMID 19407319, PMID 19724055, PMID 19848610, PMID 19904293
2018 (3), 2009 (2), 2014 (2), 2016 (2), 2015 (1), 2019 (1), 2023 (1), 2025 (1), I01CX001449 (1), P30AI060354 (1), R01HL175726 (1), R01NS117430 (1), R24TW007988 (1), U01DK071633 (1), U01NS129143 (1)